Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats

Abstract

Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular disease, especially myocardial injury. Due to their hypoglycemic effects, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are efficiently used for T2DM management. GLP-1RAs also have anti-inflammatory and antioxidative effects, and can improve cardiac function. The aim of this study was to investigate the cardioprotective effects of liraglutide, a GLP-1RA, on isoprenaline-induced myocardial injury in rats. The study included 4 groups of animals. They were pretreated with saline for 10 days + saline on days 9 and 10 (control), saline for 10 days + isoprenaline on days 9 and 10 (isoprenaline group), liraglutide for 10 days + saline on days 9 and 10 (liraglutide group), and liraglutide for 10 days and on days 9 and 10 they were administered isoprenaline. This study evaluated ECG, myocardial injury markers, oxidative stress markers, and pathohistological changes. The results showed that liraglutide mitigated the isoprenaline-induced cardiac dysfunction recorded by ECG. Liraglutide reduced serum markers of myocardial injury such as high-sensitive troponin I, aspartate aminotransferase, alanine aminotransferase, reduced TBARS, increased catalase and superoxide dismutase activity and increased reduced glutathione, and improved lipid profile. Liraglutide induced antioxidative protection and alleviated isoprenaline-induced myocardial injury.

Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus

“…These findings align with our results, corroborating the protective effect of liraglutide against DCM reported in a previous study [27]. A significant reduction in the heart weight-to-body weight ratio observed in rats with diabetes that received liraglutide treatment-a pattern commonly observed in preclinical studies and clinical trials-further supports the cardioprotective effects of liraglutide [39][40][41].…”

Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome

“…Liraglutide inhibited NADPH oxidase activity and increased the protein levels of SOD, CAT, and GPx. A recent study also showed that liraglutide-mitigated isoprenaline-induced myocardial injury in rats caused by a reduction in oxidative stress, improvement of CAT and SOD activity and markers of cardiac damage such as high-sensitivity troponin I, aspartate aminotransferase, alanine aminotransferase [ 49 ]. Moreover, GLP-1RAs appear to improve cardiac metabolism through enhanced glucose uptake, increased fatty acid oxidation, and improved mitochondrial function, contributing to better energy utilization and reduced oxidative stress in cardiac tissues [ 50 ].…”

Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists

“…The β 1 -adrenergic receptor (β 1 -AR) is involved in stress-induced cardiac injury [150]. GLP1R agonists protect the heart against the cardiotoxic effect of the β-AR agonist isoproterenol [151,152]. However, it is unknown whether GLP1R agonists protect the heart against stress-induced cardiac injury.…”